RE:RE:RE:FDA guides on how AA can be converted to full approval.
2-300 patients would be fantastic but if you listen to the latest podcast ,Links on the stocktwits board you will have just heard that Matt is predicting the trial size to be somewhere between 4-500 patients so just need to keep this in perspective and also Matt has never mentioned the use of the bio-markers in his talks in regards to running the phase 3 trials but to clarify it does state in the investior presentation that the potential use of the bio-markers in the registration trials.
I am sure we will all have most of our answers in short order but Matt also stated in the podcast that most of the answers and decisions will come out after the release of the Bracelet results so at this time am not expecting a partnership if that happens until after the Bracelet release. A buyout is the wildcard and am sure would be appreciated by all and be done....also of note and do not know if it was a slip in the podcast but I heard Matt say we have had complete responses and that was in regards to the panc trial and we all know that we have had 1 complete response so am thinking maybe it was just in the phrasing but would be a big WOW factor if we indeed did have more that one CR as no other trial would be able to compare. Can't wait for the updates and have a feeling that they are all going to be positive and help define the direction of the company.